CA2450942A1 - Method of treating hyperproliferative diseases using active vitamin d analogues - Google Patents
Method of treating hyperproliferative diseases using active vitamin d analogues Download PDFInfo
- Publication number
- CA2450942A1 CA2450942A1 CA002450942A CA2450942A CA2450942A1 CA 2450942 A1 CA2450942 A1 CA 2450942A1 CA 002450942 A CA002450942 A CA 002450942A CA 2450942 A CA2450942 A CA 2450942A CA 2450942 A1 CA2450942 A1 CA 2450942A1
- Authority
- CA
- Canada
- Prior art keywords
- hydrogen
- compound
- accordance
- alpha
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 40
- 229940046008 vitamin d Drugs 0.000 title claims abstract 19
- 201000010099 disease Diseases 0.000 title claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 2
- 230000003463 hyperproliferative effect Effects 0.000 title claims 2
- 230000001184 hypocalcaemic effect Effects 0.000 claims abstract 19
- 229930003316 Vitamin D Natural products 0.000 claims abstract 18
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract 18
- 235000019166 vitamin D Nutrition 0.000 claims abstract 18
- 239000011710 vitamin D Substances 0.000 claims abstract 18
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract 5
- 230000003211 malignant effect Effects 0.000 claims abstract 4
- 210000005170 neoplastic cell Anatomy 0.000 claims abstract 4
- 208000037147 Hypercalcaemia Diseases 0.000 claims abstract 2
- 230000000148 hypercalcaemia Effects 0.000 claims abstract 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims abstract 2
- 125000003342 alkenyl group Chemical group 0.000 claims 30
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 17
- -1 vitamin D compound Chemical class 0.000 claims 13
- 229940127089 cytotoxic agent Drugs 0.000 claims 11
- 239000002254 cytotoxic agent Substances 0.000 claims 11
- 231100000599 cytotoxic agent Toxicity 0.000 claims 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 11
- 125000002252 acyl group Chemical group 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000004991 fluoroalkenyl group Chemical group 0.000 claims 10
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 239000011203 carbon fibre reinforced carbon Chemical group 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 230000001028 anti-proliverative effect Effects 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- NEETXMRNUNEBRH-GOTXBORWSA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r,5s)-5,6-dimethylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C NEETXMRNUNEBRH-GOTXBORWSA-N 0.000 claims 3
- ZGLHBRQAEXKACO-XJRQOBMKSA-N 1alpha,25-dihydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C ZGLHBRQAEXKACO-XJRQOBMKSA-N 0.000 claims 3
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 3
- 230000000340 anti-metabolite Effects 0.000 claims 3
- 229940044684 anti-microtubule agent Drugs 0.000 claims 3
- 229940100197 antimetabolite Drugs 0.000 claims 3
- 239000002256 antimetabolite Substances 0.000 claims 3
- 230000003115 biocidal effect Effects 0.000 claims 3
- HKXBNHCUPKIYDM-CGMHZMFXSA-N doxercalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C HKXBNHCUPKIYDM-CGMHZMFXSA-N 0.000 claims 3
- 229910052697 platinum Inorganic materials 0.000 claims 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 210000004872 soft tissue Anatomy 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 102000009310 vitamin D receptors Human genes 0.000 claims 2
- 108050000156 vitamin D receptors Proteins 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 101710183280 Topoisomerase Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 229940009456 adriamycin Drugs 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000001667 episodic effect Effects 0.000 claims 1
- 229960004750 estramustine phosphate Drugs 0.000 claims 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical group ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical group COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 229960001330 hydroxycarbamide Drugs 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 229960004694 prednimustine Drugs 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical group C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/891,814 | 2001-06-26 | ||
| US09/891,814 US6503893B2 (en) | 1996-12-30 | 2001-06-26 | Method of treating hyperproliferative diseases using active vitamin D analogues |
| PCT/US2002/020475 WO2003000023A2 (en) | 2001-06-26 | 2002-06-26 | Method of treating hyperproliferative diseases using active vitamin d analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2450942A1 true CA2450942A1 (en) | 2003-01-03 |
Family
ID=25398862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002450942A Abandoned CA2450942A1 (en) | 2001-06-26 | 2002-06-26 | Method of treating hyperproliferative diseases using active vitamin d analogues |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6503893B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1408983A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2004535429A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20040015753A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1234366C (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002322346B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2450942A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL159068A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA03011307A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003000023A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040009958A1 (en) * | 1991-01-08 | 2004-01-15 | Bone Care International, Inc. | Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2 |
| US5763429A (en) * | 1993-09-10 | 1998-06-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin D analogues |
| US20020128240A1 (en) * | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
| US6566353B2 (en) * | 1996-12-30 | 2003-05-20 | Bone Care International, Inc. | Method of treating malignancy associated hypercalcemia using active vitamin D analogues |
| US6392071B1 (en) * | 1997-03-17 | 2002-05-21 | Wisconsin Alumni: Research Foundation | 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds |
| US6316642B1 (en) * | 1997-03-17 | 2001-11-13 | Wisconsin Alumni Research Foundation | 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds |
| US6087350A (en) * | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| ES2368824T3 (es) * | 1998-03-27 | 2011-11-22 | Oregon Health & Science University | Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos. |
| GB9920548D0 (en) * | 1999-08-31 | 1999-11-03 | Rhone Poulenc Rorer Sa | Treatment of hepatocellular carcinoma |
| AU2002363959B2 (en) * | 2001-12-03 | 2007-12-13 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| US20080249068A1 (en) * | 2002-09-05 | 2008-10-09 | Deluca Hector F | Method of Extending the Dose Range of Vitamin D Compounds |
| US7259143B2 (en) * | 2002-09-05 | 2007-08-21 | Wisconsin Alumni Research Foundation | Method of extending the dose range of vitamin D compounds |
| US20040058895A1 (en) * | 2002-09-18 | 2004-03-25 | Bone Care International, Inc. | Multi-use vessels for vitamin D formulations |
| US20040053895A1 (en) * | 2002-09-18 | 2004-03-18 | Bone Care International, Inc. | Multi-use vessels for vitamin D formulations |
| US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
| US20050026877A1 (en) * | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| US20050020546A1 (en) * | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| WO2005097128A1 (en) * | 2004-03-30 | 2005-10-20 | Novacea, Inc. | 1,4-bis-n-oxide azaanthracenediones and the use thereof |
| US7094775B2 (en) * | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
| US20060003950A1 (en) * | 2004-06-30 | 2006-01-05 | Bone Care International, Inc. | Method of treating prostatic diseases using a combination of vitamin D analogues and other agents |
| US20060189543A1 (en) * | 2005-02-23 | 2006-08-24 | Rosenbloom Richard A | Compositions and methods for the treatment of leukemia |
| US7914810B2 (en) * | 2005-05-06 | 2011-03-29 | Synthes Usa, Llc | Methods for the in situ treatment of bone cancer |
| SI1993559T1 (sl) | 2006-02-03 | 2017-01-31 | Opko Renal, Llc | Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3 |
| HUE037309T2 (hu) | 2006-06-21 | 2018-08-28 | Opko Ireland Global Holdings Ltd | Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer |
| TW200833345A (en) * | 2006-11-01 | 2008-08-16 | Novacea Inc | Use of vitamin D compounds and mimics thereof to enhance delivery of therapeutics and oxygen to tumors and other tissues |
| WO2008097646A1 (en) * | 2007-02-09 | 2008-08-14 | Schering Corporation | Methods to treat and/or prevent mucositis |
| DK3225243T3 (da) * | 2007-04-25 | 2025-09-29 | Opko Renal Llc | Metode til sikker og effektiv behandling og forebyggelse af sekundær hyperparatyreoidisme ved kronisk nyresygdom |
| KR101495578B1 (ko) | 2007-04-25 | 2015-02-25 | 사이토크로마 인코포레이티드 | 비타민 ｄ 부족 및 결핍의 치료 방법 |
| WO2008134512A1 (en) | 2007-04-25 | 2008-11-06 | Cytochroma Inc. | Oral controlled release compositions comprising vitamin d compound and waxy carrier |
| CA2714996C (en) | 2008-04-02 | 2020-04-07 | Cytochroma Inc. | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
| WO2009151569A2 (en) * | 2008-06-09 | 2009-12-17 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
| AU2010208323B2 (en) | 2009-01-27 | 2016-03-10 | Berg Llc | Vitamin D3 and analogs thereof for alleviating side effects associated with chemotherapy |
| MX366076B (es) | 2009-08-14 | 2019-06-27 | Berg Llc | Vitamina d3 y analogos de la misma para tratar alopecia. |
| EP3636280B1 (en) | 2010-03-29 | 2025-05-14 | EirGen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| KR20160013201A (ko) | 2013-05-29 | 2016-02-03 | 버그 엘엘씨 | 비타민 d를 이용한 화학요법 유발 탈모증의 예방 또는 완화 |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| CN106674306A (zh) * | 2015-01-13 | 2017-05-17 | 南京理工大学 | 维生素d2糖苷类似物、合成及应用 |
| UA129792C2 (uk) | 2016-03-28 | 2025-08-06 | Ейрджен Фарма Лтд. | Способи лікування вітаміном d |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2383446A (en) | 1941-06-04 | 1945-08-28 | Du Pont | Antirachitic materials and processes for their production |
| US3697559A (en) | 1971-02-25 | 1972-10-10 | Wisconsin Alumni Res Found | 1,25-dihydroxycholecalciferol |
| US3741996A (en) | 1971-12-02 | 1973-06-26 | Wisconsin Alumni Res Found | 1{60 -hydroxycholecalciferol |
| US4670190A (en) | 1973-01-10 | 1987-06-02 | Hesse Robert H | 1-α-hydroxy vitamin D compounds and process for preparing same |
| US3907843A (en) | 1974-06-14 | 1975-09-23 | Wisconsin Alumni Res Found | 1{60 -Hydroxyergocalciferol and processes for preparing same |
| US4202829A (en) | 1978-01-05 | 1980-05-13 | Wisconsin Alumni Research Foundation | Process for preparing 1α-hydroxylated compounds |
| US4260549A (en) | 1979-05-21 | 1981-04-07 | Wisconsin Alumni Research Foundation | Process for preparing 1α-hydroxylated compounds |
| US4195027A (en) | 1978-01-16 | 1980-03-25 | Wisconsin Alumni Research Foundation | Process for preparing 1α-hydroxylated compounds |
| NL188286C (nl) | 1978-01-16 | 1992-05-18 | Wisconsin Alumni Res Found | Werkwijze voor het bereiden van een 1alfa-hydroxyvitamine d verbinding. |
| US4225596A (en) | 1978-10-13 | 1980-09-30 | Wisconsin Alumni Research Foundation | Method for treating calcium imbalance and improving calcium absorption in mammals |
| US4234495A (en) | 1979-09-10 | 1980-11-18 | Wisconsin Alumni Research Foundation | Process for preparing 1α-hydroxyvitamin D compounds from 1α-hydroxy-3,5-cyclovitamin D compounds |
| US4362710A (en) | 1980-07-04 | 1982-12-07 | Nissan Gosei Kogyo Co., Ltd. | Feeds for baby pigs, process for preparing the same and method of breeding baby pigs |
| JPS57149224A (en) | 1981-03-13 | 1982-09-14 | Chugai Pharmaceut Co Ltd | Tumor-suppressing agent |
| CH655396B (cg-RX-API-DMAC7.html) | 1981-11-11 | 1986-04-15 | ||
| US4508651A (en) | 1983-03-21 | 1985-04-02 | Hoffmann-La Roche Inc. | Synthesis of 1α,25-dihydroxyergocalciferol |
| DE3448412C2 (cg-RX-API-DMAC7.html) | 1983-05-09 | 1991-12-12 | Wisconsin Alumni Res Found | |
| US4689180A (en) | 1984-01-30 | 1987-08-25 | Wisconsin Alumni Research Foundation | 1α,25-dihydroxy-22Z-dehydroxyvitamin D compound |
| US4588716A (en) | 1984-05-04 | 1986-05-13 | Wisconsin Alumni Research Foundation | Method for treating metabolic bone disease in mammals |
| US4555364A (en) | 1984-11-01 | 1985-11-26 | Wisconsin Alumni Research Foundation | Method for preparing 1-hydroxyvitamin D compounds |
| US4554106A (en) | 1984-11-01 | 1985-11-19 | Wisconsin Alumni Research Foundation | Method for preparing 1α-hydroxyvitamin D compounds |
| US4661294A (en) | 1985-03-18 | 1987-04-28 | The General Hospital Corporation | Biologically active 1-thio derivatives of vitamin D |
| IL78342A (en) | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
| WO1987000834A1 (en) | 1985-08-02 | 1987-02-12 | Leo Pharmaceutical Products Ltd. A/S | Novel vitamin d analogues |
| US4833125A (en) | 1986-12-05 | 1989-05-23 | The General Hospital Corporation | Method of increasing bone mass |
| JP2550391B2 (ja) | 1988-06-30 | 1996-11-06 | 日清製粉株式会社 | １β−ヒドロキシビタミンＤ▲下２▼およびＤ▲下３▼の製造方法 |
| US5602116A (en) | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| US5104864A (en) | 1988-08-02 | 1992-04-14 | Bone Care International, Inc. | Method for treating and preventing loss of bone mass |
| CA1333616C (en) | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| US5372996A (en) | 1989-03-10 | 1994-12-13 | Endorecherche, Inc. | Method of treatment of androgen-related diseases |
| JP2645130B2 (ja) | 1989-03-31 | 1997-08-25 | 日清製粉株式会社 | ステロイド誘導体 |
| GB2229921B (en) | 1989-04-05 | 1992-12-16 | Chugai Pharmaceutical Co Ltd | Treatment for hyperparathyroidism with use of vitamin d derivatives |
| US5801164A (en) | 1990-09-21 | 1998-09-01 | Bone Care International, Inc. | Methods of treating osteoporosis prophylactically or therapeutically |
| US5763428A (en) | 1990-09-21 | 1998-06-09 | Bone Care International, Inc. | Methods of treating skin disorders with novel 1a-hydroxy vitamin D4 compounds and derivatives thereof |
| US5798345A (en) * | 1990-09-21 | 1998-08-25 | Bone Care International, Inc. | Method of inhibiting the hyperproliferation of malignant cells |
| KR100231809B1 (ko) | 1990-09-21 | 1999-12-01 | 로버트 에이. 벡크만 | 1알파-하이드록시 비타민 d4 및 이의 중간체 및 동족체, 및 이를 포함하는 약제학적 조성물 |
| US6025346A (en) | 1990-09-21 | 2000-02-15 | Bone Care International, Inc. | 1α-hydroxy vitamin D4 and novel intermediates and analogues |
| US5789397A (en) | 1991-01-08 | 1998-08-04 | Bone Care International, Inc. | Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2 |
| US6166000A (en) | 1991-01-08 | 2000-12-26 | Bone Care International, Inc. | Methods for preparation and use of 1α,24(S)-Dihydroxy vitamin . D.sub2 |
| US6538037B2 (en) * | 1991-01-08 | 2003-03-25 | Bone Care International, Inc. | Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2 |
| EP0914825B1 (en) | 1991-01-08 | 2003-05-21 | Bone Care International, Inc. | Methods for preparation of 1 alpha, 24-dihydroxy vitamin D2 |
| DK0503630T3 (da) | 1991-03-13 | 1996-01-29 | Kuraray Co | Cyclohexantriolderivater |
| AU650751B2 (en) | 1991-05-28 | 1994-06-30 | Wisconsin Alumni Research Foundation | Novel synthesis of 19-nor vitamin D compounds |
| AU666654B2 (en) | 1991-05-28 | 1996-02-22 | Procter & Gamble Company, The | Calcium, trace mineral, vitamin D and drug therapy combinations |
| DE69125836T2 (de) | 1991-11-14 | 1997-12-18 | Quantum Corp | Spindel- und Nabenausrüstung |
| JP2927368B2 (ja) | 1992-01-29 | 1999-07-28 | ボーン ケア インターナショナル インコーポレイテッド | １α−ヒドロキシ−２４−ＥＰＩ−ビタミンＤ▲下４▼ |
| EP0562497A1 (en) | 1992-03-27 | 1993-09-29 | Nisshin Flour Milling Co., Ltd. | 1 alpha-hydroxy vitamins D7 and D4' processes for the preparation thereof and pharmaceutical compositions |
| JP3179495B2 (ja) * | 1992-08-28 | 2001-06-25 | ボーン ケア インターナショナル インコーポレイテッド | １α，２４（Ｓ）−ジヒドロキシビタミンＤ▲下２▼の調製及び使用方法 |
| US5350745A (en) | 1993-01-29 | 1994-09-27 | Lunar Corporation | Treatment of myocardial failure |
| US5763429A (en) | 1993-09-10 | 1998-06-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin D analogues |
| ATE168367T1 (de) | 1994-01-20 | 1998-08-15 | Duphar Int Res | Vitamin-d-derivate und verfahren zu deren herstellung |
| US5763427A (en) * | 1995-03-31 | 1998-06-09 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
| DE19549243A1 (de) | 1995-12-21 | 1997-06-26 | Schering Ag | Pharmazeutische Präparate enthaltend Clathrate von Cyclodextrinen und nichtnatürliche Vitamin D-Analoga |
| US6034074A (en) | 1996-09-13 | 2000-03-07 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a Vitamin D compound |
| WO1998020123A2 (en) * | 1996-11-04 | 1998-05-14 | Institut Curie | Stable cell lines expressing the cftr protein or a mutant of this protein, tool for selecting molecules having an effect on the intracellular transport of these proteins |
| AUPO727097A0 (en) | 1997-06-10 | 1997-07-03 | Unisearch Limited | Method of treatment of hepatoma and pharmaceutical compositions for use therein |
| US6087350A (en) | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| JP2002507415A (ja) | 1998-03-25 | 2002-03-12 | キュタノジェン， インコーポレイテッド | 癌の予防および処置のための方法 |
| ES2368824T3 (es) * | 1998-03-27 | 2011-11-22 | Oregon Health & Science University | Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos. |
| US20010002396A1 (en) | 1998-07-16 | 2001-05-31 | Charles Achkar | Compositions and methods of treating skin conditions |
| ATE294585T1 (de) | 1999-09-29 | 2005-05-15 | Colotech As | Vorbeugung von kolorektalkrebs |
| EP1276482B1 (en) | 2000-03-02 | 2008-01-16 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Combination chemotherapy |
-
2001
- 2001-06-26 US US09/891,814 patent/US6503893B2/en not_active Expired - Lifetime
-
2002
- 2002-06-26 CA CA002450942A patent/CA2450942A1/en not_active Abandoned
- 2002-06-26 KR KR10-2003-7016888A patent/KR20040015753A/ko not_active Ceased
- 2002-06-26 CN CNB028128818A patent/CN1234366C/zh not_active Expired - Fee Related
- 2002-06-26 AU AU2002322346A patent/AU2002322346B2/en not_active Ceased
- 2002-06-26 MX MXPA03011307A patent/MXPA03011307A/es active IP Right Grant
- 2002-06-26 EP EP02756332A patent/EP1408983A4/en not_active Withdrawn
- 2002-06-26 IL IL15906802A patent/IL159068A0/xx unknown
- 2002-06-26 WO PCT/US2002/020475 patent/WO2003000023A2/en not_active Ceased
- 2002-06-26 JP JP2003506479A patent/JP2004535429A/ja active Pending
-
2003
- 2003-01-07 US US10/337,506 patent/US6680309B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03011307A (es) | 2004-06-08 |
| CN1520302A (zh) | 2004-08-11 |
| US20020025950A1 (en) | 2002-02-28 |
| JP2004535429A (ja) | 2004-11-25 |
| EP1408983A4 (en) | 2007-05-09 |
| US6503893B2 (en) | 2003-01-07 |
| WO2003000023A2 (en) | 2003-01-03 |
| EP1408983A2 (en) | 2004-04-21 |
| CN1234366C (zh) | 2006-01-04 |
| IL159068A0 (en) | 2004-05-12 |
| KR20040015753A (ko) | 2004-02-19 |
| WO2003000023A3 (en) | 2003-07-31 |
| US6680309B2 (en) | 2004-01-20 |
| AU2002322346B2 (en) | 2006-10-26 |
| US20030130242A1 (en) | 2003-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2450942A1 (en) | Method of treating hyperproliferative diseases using active vitamin d analogues | |
| JP2004535429A5 (cg-RX-API-DMAC7.html) | ||
| CA2546730A1 (en) | A method for the treatment of malignant diseases by inhibiting nucleolin | |
| JP2004535439A5 (cg-RX-API-DMAC7.html) | ||
| JP2003528920A (ja) | 血管損傷性活性を有する併用療法 | |
| JP2004535441A5 (cg-RX-API-DMAC7.html) | ||
| Serkies et al. | Chemotherapy in the primary treatment of cervical carcinoma | |
| CA2451037A1 (en) | Method of treating malignancy associated hypercalcemia using active vitamin d analogues | |
| RU2004137801A (ru) | Композиция для терапии рака сапонинами или сапогенинами | |
| RU2007104053A (ru) | Лечение рака | |
| Lale Atahan et al. | Two cases of Stevens–Johnson syndrome: toxic epidermal necrolysis possibly induced by amifostine during radiotherapy | |
| US6288111B1 (en) | Combination cisplatin/tamoxifen therapy for human cancers | |
| Di Legge et al. | Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer | |
| Cetnar et al. | A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer | |
| Brada et al. | Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin. | |
| US6593303B1 (en) | Anti-tumor synergetic composition | |
| Glaser et al. | Weekly cisplatinum concomitant with radical radiotherapy in the treatment of advanced head and neck cancer | |
| Cristofanilli et al. | Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the MD Anderson Cancer Center experience | |
| Karnofsky | Hormonal and chemical methods in the treatment of cancer | |
| US20080318880A1 (en) | Neoadjuvant treatment of Breast Cancer | |
| Fischer et al. | 5078 Treatment of leptomeningeal involvement of breast cancer with high-dose methotrexate and ifosfamide | |
| US20060142287A1 (en) | Use of a combination of dppe with other chemotherapeutic agents for the treatment of breast cancer | |
| Uyama et al. | Histological evaluation of radiochemotherapy for prostatic cancer: early results of a pilot study | |
| Giles et al. | A trial of 1−(2− chlorethyI)− 3−(4− methyl‐cyclohexyl)‐1‐nitrosourea in the treatment of patients with advanced gastro‐intestinal cancer | |
| Merlin et al. | Comparison of P-glycoprotein expression and daunorubicin cellular accumulation in adult and childhood acute leukemias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |